NEW YORK (360Dx) – RenalytixAI announced today that it has signed an agreement with Akesogen for a partnership that aims to increase testing capacity and support pharmaceutical services.
Through the joint venture, called Renx AI Labs, the partnership will provide services directly to health systems and pharmaceutical companies located in the US. The venture will allow RenalytixAI to operate outside of its New York City-based clinical lab at JLABS, a Johnson & Johnson Innovation center.
In a statement, the partners said that Akesogen's 14,000-square-foot CLIA-certified and CAP-accredited lab will allow RenalytixAI to scale up its operations immediately in support of additional partnerships. The JV will also help RenalytixAI support prospective revenue-generating contract research, as well as clinical diagnostic and trial services linked to the firm's business model.
Based in the Atlanta area, Akesogen is an integrated genomics, genetics, and biobanking company.
RenalytixAI noted that the JV will support pharmaceutical company initiatives by including AI-enabled diagnostics — starting with the KidneyIntelX assay — to improve patient characterization and targeting of patients for drug clinical trials for renal disease. The firm said that Renx AI labs has the ability to develop companion diagnostic tools "under stringent quality control processes." Where does the quote begin?
Financial and other terms of the agreement were not disclosed.